


Advanced Chemical Industries Limited


Condensed Interim Financial Statements
2nd quarter ended report 2023-2024
for the six months period ended on 31 December 2023


Advanced Chemical Industries Limited
Statement of financial position
Unaudited

	Note	Figures in '000' Taka	
		As at 31 December 2023	As at 30 June 2023
Assets			
Property, plant and equipment	2	15,512,744	14,976,956
Right-of-use assets		672,387	676,828
Investments	3	2,993,802	2,905,427
Intangible assets		648	1,080
Biological assets		39,280	36,570
Non-current assets		19,218,861	18,596,861
Inventories	4	8,386,268	6,761,997
Trade receivables	5	2,834,940	2,660,997
Other receivables		1,418,650	829,986
Inter-company receivables	6	36,965,093	33,842,811
Advances, deposits and prepayments	7	2,111,501	1,063,519
Cash and cash equivalents		1,147,865	1,179,664
Current assets		52,864,317	46,338,974
Total assets		72,083,178	64,935,835
Equity			
Share capital		762,056	762,056
Share premium		402,310	402,310
Reserves		4,547,151	4,552,487
Retained earnings		17,069,659	15,703,474
Total equity		22,781,176	21,420,328
Liabilities			
Employee benefits	8	1,453,785	1,308,810
Long term borrowings	9	1,794,094	1,505,491
Non-current portion of lease liabilities		470,317	473,566
Deferred tax liabilities		363,428	404,137
Non-current liabilities		4,081,624	3,692,004
Bank overdraft		5,439,690	5,847,200
Loans and borrowings	10	27,400,974	24,724,913
Current portion of lease liabilities		176,695	167,786
Trade payables		1,979,860	1,148,133
Inter-company payables	11	5,115,946	4,203,826
Other payables	12	4,454,517	3,432,299
Unclaimed/unpaid dividend account		384,734	80,015
Current tax liabilities		267,963	219,331
Current liabilities		45,220,378	39,823,503
Total liabilities		49,302,002	43,515,507
Total equity and liabilities		72,083,178	64,935,835
Net asset value (NAV) per share (in Taka)		298.94	281.09


Managing Director


Director


Chief Financial Officer


Company Secretary

Advanced Chemical Industries Limited
Statement of profit or loss
Unaudited

	Note	Figures in '000' Taka			
		For half year from		For the 2nd quarter from	
		July 2023 to December 2023	July 2022 to December 2022	October 2023 to December 2023	October 2022 to December 2022
Revenue	13	17,545,242	14,651,284	8,810,839	7,808,504
Cost of sales	14	(10,418,350)	(8,766,662)	(5,332,847)	(4,811,089)
Gross profit		7,126,892	5,884,622	3,477,993	2,997,415
Administrative, selling and distribution expenses	15	(5,709,960)	(5,094,072)	(2,885,225)	(2,566,025)
Other income		918,656	611,549	814,065	510,062
Operating profit		2,335,588	1,402,098	1,406,832	941,452
Gain on disposal of investment in joint ventures and associates		-	249,078	-	249,078
Net finance costs		(122,078)	(175,312)	(21,780)	(61,336)
Profit before contribution to WPPF		2,213,509	1,475,864	1,385,052	1,129,194
Contribution to WPPF		(110,675)	(73,793)	(69,253)	(56,460)
Profit before tax		2,102,834	1,402,071	1,315,800	1,072,735
Income tax expense		(431,826)	(300,891)	(212,926)	(178,368)
Profit after tax		1,671,008	1,101,180	1,102,874	894,366
Earnings per share					
Basic and diluted earnings per share (EPS) (in Taka)		21.93	14.45	14.47	11.74



 Managing Director



 Director



 Chief Financial Officer



 Company Secretary

Advanced Chemical Industries Limited
Statement of profit or loss and other comprehensive income
Unaudited

	Figures in '000' Taka			
	For half year from		For the 2nd quarter from	
	July 2023 to December 2023	July 2022 to December 2022	October 2023 to December 2023	October 2022 to December 2022
Profit after tax	1,671,008	1,101,180	1,102,874	894,366
Other comprehensive income:				
Change in fair value of FVOCI financial assets	(5,930)	(24,258)	-	2,695
Income tax on FVOCI financial assets	593	2,426	-	(269)
Other comprehensive income, net of tax	(5,337)	(21,832)	-	2,426
Total comprehensive income	1,665,671	1,079,348	1,102,874	896,793

Advanced Chemical Industries Limited
Statement of changes in equity
Unaudited

	Figures in '000' Taka						
	For the half year from July 2023 to December 2023						
	Share capital	Share premium	Capital reserve	FVOCI reserve	Revaluation reserve	Retained earnings	Total equity
Balance at 1 July 2023	762,056	402,310	1,671	393,444	4,157,372	15,703,474	21,420,328
Total comprehensive income							
Profit after tax	-	-	-	-	-	1,671,008	1,671,008
Other comprehensive income, net of tax	-	-	-	(5,337)	-	-	(5,337)
Total comprehensive income	-	-	-	(5,337)	-	1,671,008	1,665,671
Transaction with owners of the Company							
Share premium	-	-	-	-	-	-	-
Stock dividend	-	-	-	-	-	-	-
Cash dividend	-	-	-	-	-	(304,823)	(304,823)
Total transactions with owners of the Company	-	-	-	-	-	(304,823)	(304,823)
Balance at 31 December 2023	762,056	402,310	1,671	388,108	4,157,372	17,069,659	22,781,176
	For the half year from July 2022 to December 2022						
	Share capital	Share premium	Capital reserve	FVOCI reserve	Revaluation reserve	Retained earnings	Total equity
	Share capital	Share premium	Capital reserve	FVOCI reserve	Revaluation reserve	Retained earnings	Total equity
Balance at 1 July 2022	725,768	402,310	1,671	401,449	4,711,245	14,426,635	20,669,079
Total comprehensive income							
Profit after tax	-	-	-	-	-	1,101,180	1,101,180
Other comprehensive income, net of tax	-	-	-	(21,832)	-	-	(21,832)
Total comprehensive income	-	-	-	(21,832)	-	1,101,180	1,079,348
Transaction with owners of the Company							
Share premium	-	-	-	-	-	-	-
Stock dividend	36,288	-	-	-	-	(36,288)	-
Cash dividend	-	-	-	-	-	(362,884)	(362,884)
Total transactions with owners of the Company	36,288	-	-	-	-	(399,172)	(362,884)
Balance at 31 December 2022	762,056	402,310	1,671	379,618	4,711,245	15,128,643	21,385,543


Advanced Chemical Industries Limited
Statement of cash flows
Unaudited


	Figures in '000' Taka	
	For half year from	
	July 2023 to December 2023	July 2022 to December 2022
Cash flows from operating activities		
Cash receipts from customers and others	17,125,610	14,783,243
Cash paid to suppliers and employees	(16,219,396)	(13,143,543)
Cash generated from / (used in) operating activities	906,214	1,639,700
Paid to WPPF	(144,544)	(11,488)
Finance costs paid	(92,664)	(151,173)
Income tax paid	(423,311)	(301,638)
	(660,519)	(464,299)
Net cash from / (used in) operating activities*	16	245,695
Cash flows from investing activities		
Acquisition of property, plant and equipment	(331,508)	(156,105)
Payments for capital work-in-progress	(482,480)	(922,428)
Sale proceeds from property, plant and equipment	223	703
Purchase of biological assets	(1,184)	(3,673)
Dividend received	352,000	-
Proceeds from disposal of investment in joint ventures and associates	-	583,107
Investment	(94,305)	64,000
Net cash from / (used in) investing activities	(557,253)	(434,397)
Cash flows from financing activities		
Inter-company debts received/(paid)	(2,187,172)	(3,417,001)
Dividend paid	(103)	(720)
Payment for lease liabilities	(92,425)	(81,398)
Short-term bank loan received/(paid)	2,634,620	1,011,819
Long-term bank loan received/(paid)	330,045	528,527
Net cash from / (used in) financing activities	684,965	(1,958,773)
Net increase / (decrease) in cash and cash equivalents	373,407	(1,217,769)
Opening cash and cash equivalents	(4,667,536)	(2,563,383)
Effect of movements in exchange rates on cash held	2,305	2,344
Closing cash and cash equivalents	(4,291,824)	(3,778,808)
Closing balance represents		
Cash and cash equivalents	1,147,865	997,511
Bank overdraft	(5,439,690)	(4,776,319)
	(4,291,824)	(3,778,808)
Net operating cash flows per share (NOCFPS) (in Taka)	3.22	15.42


*See Note 16 for reconciliation of net operating cash flow.


Advanced Chemical Industries Limited
Consolidated statement of financial position
Unaudited

	Note	Figures in '000' Taka	
		As at 31 December 2023	As at 30 June 2023
Assets			
Property, plant and equipment	2 (a)	33,198,846	31,715,817
Right-of-use assets		3,051,089	3,082,582
Equity-accounted investees		2,057,109	2,058,057
Other investments		1,096,439	1,027,172
Intangible assets		1,442,903	1,409,150
Biological assets		39,280	36,570
Deferred tax assets		548,134	341,109
Non-current assets		41,433,799	39,670,457
Inventories	4 (a)	24,535,308	21,791,856
Trade receivables	5 (a)	19,421,374	16,648,869
Other receivables		1,430,298	1,103,491
Receivable from joint-ventures and associates	6 (a)	965	965
Advances, deposits and prepayments	7 (a)	6,449,117	3,291,524
Current tax assets		355,132	343,736
Short term investments		192,727	2,784,452
Cash and cash equivalents		3,622,639	5,272,772
Current assets		56,007,559	51,237,665
Total assets		97,441,359	90,908,122
Equity			
Share capital		762,056	762,056
Share premium		1,254,116	1,254,116
Reserves		5,957,023	6,130,774
Retained earnings		(431,132)	515,470
Equity attributable to owners of the Company		7,542,063	8,662,417
Non-controlling interests		1,672,174	1,884,856
Total equity		9,214,238	10,547,273
Liabilities			
Employee benefits	8 (a)	1,902,475	1,720,980
Long term borrowings	9 (a)	7,688,827	6,047,144
Non-current portion of lease liabilities		2,375,670	2,392,020
Non-current liabilities		11,966,972	10,160,144
Bank overdraft		8,524,189	8,427,736
Loans and borrowings	10 (a)	48,976,034	44,885,490
Current portion of lease liabilities		500,613	484,100
Trade payables		8,432,130	7,035,969
Other payables	12 (a)	9,104,494	9,281,693
Unclaimed/unpaid dividend account		722,690	85,717
Current liabilities		76,260,149	70,200,706
Total liabilities		88,227,121	80,360,849
Total equity and liabilities		97,441,359	90,908,122
Net asset value (NAV) per share (in Taka)	<i>18</i>	98.97	113.67


Managing Director


Director


Chief Financial Officer


Company Secretary

Advanced Chemical Industries Limited
Consolidated statement of profit or loss
Unaudited

Figures in '000' Taka

	Note	For half year from		For the 2nd quarter from	
		July 2023 to December 2023	July 2022 to December 2022	October 2023 to December 2023	October 2022 to December 2022
Revenue	13 (a)	62,443,329	57,064,982	32,038,033	30,280,936
Cost of sales	14 (a)	(47,665,312)	(43,940,994)	(24,582,226)	(23,271,170)
Gross profit		14,778,017	13,123,989	7,455,807	7,009,766
Administrative, selling and distribution expenses	15 (a)	(11,258,637)	(10,086,630)	(5,674,101)	(5,211,584)
Other income/ (loss)		112,662	244,329	(30,370)	47,179
Operating profit		3,632,043	3,281,687	1,751,336	1,845,361
Share of the profit of equity accounted investees		317,447	74,241	159,847	32,055
Gain on disposal of investment in joint ventures and associates		-	416,029	-	416,029
Net finance costs		(3,096,259)	(2,419,221)	(1,561,785)	(1,241,706)
Profit before contribution to WPPF		853,231	1,352,736	349,398	1,051,738
Contribution to WPPF		(196,740)	(181,399)	(120,831)	(118,108)
Profit before tax		656,491	1,171,337	228,567	933,630
Income tax expense		(1,147,951)	(992,012)	(578,933)	(568,320)
Profit/ (loss) after tax		(491,460)	179,325	(350,366)	365,310
Profit/ (loss) attributable to:					
Owners of the Company		(641,780)	(136,209)	(483,888)	149,596
Non-controlling interests		150,320	315,535	133,522	215,714
Profit/ (loss) after tax		(491,460)	179,325	(350,366)	365,310
Earnings per share					
Basic and diluted earnings per share (EPS) (in Taka)	18	(8.42)	(1.79)	(6.35)	1.96


Managing Director


Director


Chief Financial Officer


Company Secretary

Advanced Chemical Industries Limited
Consolidated statement of profit or loss and other comprehensive income
Unaudited

	Figures in '000' Taka			
	For half year from		For the 2nd quarter from	
	July 2023 to December 2023	July 2022 to December 2022	October 2023 to December 2023	October 2022 to December 2022
Profit/ (loss) after tax	(491,460)	179,325	(350,366)	365,310
Other comprehensive income:				
Foreign operations - foreign currency translation differences	(183,663)	(12,022)	(145,596)	1,181
Change in fair value of FVOCI financial assets	(5,981)	(28,290)	784	(314)
Income tax on other comprehensive income	598	2,829	(78)	31
Other comprehensive income, net of tax	(189,047)	(37,482)	(144,891)	898
Total comprehensive income	(680,507)	141,843	(495,257)	366,208
Total comprehensive income attributable to:				
Owners of the Company				
Profit/ (loss) after tax	(641,780)	(136,209)	(483,888)	149,596
Other comprehensive income	(173,751)	(28,841)	(135,272)	3,281
	(815,531)	(165,050)	(619,161)	152,877
Non-controlling interests				
Profit/ (loss) after tax	150,320	315,535	133,522	215,714
Other comprehensive income	(15,296)	(8,642)	(9,618)	(2,382)
	135,024	306,893	123,904	213,331
Total comprehensive income	(680,507)	141,843	(495,257)	366,208

Advanced Chemical Industries Limited
Consolidated statement of changes in equity
Unaudited

Figures in '000' Taka
For the half year from July 2023 to December 2023

	Attributable to owners of the Company							Non-controlling Interests	Total equity	
	Share capital	Share premium	Capital reserve	Translation reserve	FVOCI reserve	Revaluation reserve	Retained earnings			Total
Balance at 1 July 2023	762,056	1,254,116	1,671	(120,987)	389,978	5,860,112	515,470	8,662,417	1,884,856	10,547,273
Total comprehensive income										
Profit/ (loss) after tax	-	-	-	-	-	-	(641,780)	(641,780)	150,320	(491,460)
Other comprehensive income, net of tax	-	-	-	(168,390)	(5,361)	-	-	(173,751)	(15,296)	(189,047)
Total comprehensive income	-	-	-	(168,390)	(5,361)	-	(641,780)	(815,531)	135,024	(680,507)
Transaction with owners of the Company										
Share premium	-	-	-	-	-	-	-	-	-	-
Stock dividend	-	-	-	-	-	-	-	-	-	-
Cash dividend	-	-	-	-	-	-	(304,823)	(304,823)	(347,706)	(652,529)
Total transactions with owners of the Company	-	-	-	-	-	-	(304,823)	(304,823)	(347,706)	(652,529)
Balance at 31 December 2023	762,056	1,254,116	1,671	(289,378)	384,617	5,860,112	(431,132)	7,542,063	1,672,174	9,214,238

For the half year from July 2022 to December 2022

	Attributable to owners of the Company							Non-controlling Interests	Total equity	
	Share capital	Share premium	Capital reserve	Translation reserve	FVOCI reserve	Revaluation reserve	Retained earnings			Total
Balance at 1 July 2022	725,768	1,231,094	1,671	(80,757)	399,525	6,630,048	1,397,376	10,304,725	1,899,967	12,204,692
Total comprehensive income										
Profit/ (loss) after tax	-	-	-	-	-	-	(136,209)	(136,209)	315,535	179,325
Other comprehensive income, net of tax	-	-	-	(5,166)	(23,674)	-	-	(28,841)	(8,642)	(37,482)
Total comprehensive income	-	-	-	(5,166)	(23,674)	-	(136,209)	(165,050)	306,893	141,843
Transaction with owners of the Company										
Share premium	-	-	-	-	-	-	-	-	-	-
Stock dividend	36,288	-	-	-	-	-	(36,288)	-	-	-
Cash dividend	-	-	-	-	-	-	(362,884)	(362,884)	(194,707)	(557,591)
Capital contribution by non-controlling interest	-	-	-	-	-	-	-	-	1,000	1,000
Total transactions with owners of the Company	36,288	-	-	-	-	-	(399,172)	(362,884)	(193,707)	(556,591)
Balance at 31 December 2022	762,056	1,231,094	1,671	(85,923)	375,850	6,630,048	861,995	9,776,792	2,013,152	11,789,944

Advanced Chemical Industries Limited
Consolidated statement of cash flows
Unaudited

	Figures in '000' Taka	
	For half year from	
	July 2023 to December 2023	July 2022 to December 2022
Cash flows from operating activities		
Cash receipts from customers and others	58,906,614	53,504,740
Cash paid to suppliers and employees	(61,739,007)	(56,598,868)
Cash generated from / (used in) operating activities	(2,832,393)	(3,094,128)
Paid to WPPF	(328,233)	(75,372)
Finance costs paid	(2,321,230)	(1,749,285)
Income tax paid	(1,288,202)	(1,205,232)
	(3,937,665)	(3,029,889)
Net cash from / (used in) operating activities *	(6,770,058)	(6,124,017)
	16 (a)	
Cash flows from investing activities		
Acquisition of property, plant and equipment	(770,282)	(271,080)
Payments for capital work-in-progress	(1,657,315)	(1,905,522)
Sale proceeds from property, plant and equipment	223	2,703
Purchase of biological assets	(1,184)	(3,673)
Dividend received	352,000	-
Proceeds from disposal of investment in joint ventures and associates	-	583,107
Short term investments	2,591,725	-
Long term investments	(191,605)	(57,600)
Net cash from / (used in) investing activities	323,563	(1,652,066)
Cash flows from financing activities		
Inter-company debts received/(paid)	-	8,450
Dividend paid	(103)	(720)
Payment for lease liabilities	(248,571)	(179,942)
Dividend paid to non-controlling interests	(6)	(6)
Short-term bank loan received/(paid)	3,144,331	3,239,216
Long-term bank loan received/(paid)	1,803,758	2,385,977
Net cash from / (used in) financing activities	4,699,410	5,452,976
Net increase / (decrease) in cash and cash equivalents	(1,747,085)	(2,323,107)
Opening cash and cash equivalents	(3,154,964)	(1,968,368)
Effect of movements in exchange rates on cash held	499	7,414
Closing cash and cash equivalents	(4,901,550)	(4,284,062)
Closing balance represents		
Cash and cash equivalents	3,622,639	2,862,974
Bank overdraft	(8,524,189)	(7,147,035)
	(4,901,550)	(4,284,062)
Net operating cash flows per share (NOCFPS) (in Taka)	18	(88.84)
		(80.36)

*See Note 16(a) for reconciliation of consolidated net operating cash flow.

Advanced Chemical Industries Limited
Notes to the financial statements
as at and for the 2nd quarter ended on 31 December 2023
Unaudited

1 Selected explanatory notes

These financial statements have been prepared in line with Accounting Policies as adopted in the preparation of financial statements for the year ended from 1 July 2022 to 30 June 2023. This interim financial report includes only those selected explanatory notes as deemed appropriate for better understanding of unaudited financial statements.

	Figures in '000' Taka	
	31 December 2023	30 June 2023
	<u>Taka</u>	<u>Taka</u>
2 Property, plant and equipment		
Opening balance	18,382,467	16,402,682
Additions during the period	785,844	2,005,194
Disposals and adjustments	(6,422)	(25,408)
Accumulated depreciation	(3,649,145)	(3,405,512)
Closing balance	<u>15,512,744</u>	<u>14,976,956</u>

2 (a) Consolidated property, plant and equipment

Opening balance	41,925,146	37,802,012
Additions during the period	2,330,247	4,202,326
Disposals and adjustments	20,561	(79,192)
Accumulated depreciation	(11,077,108)	(10,209,329)
Closing balance	<u>33,198,846</u>	<u>31,715,817</u>

3 Investments

Investment in subsidiaries	1,759,436	1,751,736
Investment in joint ventures	185,000	185,000
Investment in associates	687,962	566,357
Investment in shares	513,685	519,615
Investment in FDR/ other deposits	121,319	156,319
Impairment	(273,600)	(273,600)
	<u>2,993,802</u>	<u>2,905,427</u>

4 Inventories

Raw materials	3,120,410	2,599,194
Packing materials	787,133	776,886
Work-in-process	338,976	303,959
Finished goods	3,652,415	3,196,236
Goods in transit	978,424	500,861
Stores and spares	126,884	104,282
Allowance for inventory	(617,974)	(719,421)
	<u>8,386,268</u>	<u>6,761,997</u>

		Figures in '000' Taka	
		31 December 2023	30 June 2023
		Taka	Taka
4 (a)	Consolidated inventories		
	Raw materials	7,451,995	7,371,455
	Packing materials	903,571	929,879
	Work-in-process	821,399	836,333
	Finished goods	14,561,063	12,577,234
	Goods in transit	1,705,777	1,024,059
	Stores and spares	429,365	365,970
	Allowance for inventory	(1,337,861)	(1,313,074)
		24,535,308	21,791,856
5	Trade receivables		
	Debts due over six months	1,549,103	1,647,248
	Debts due below six months	2,094,430	1,740,065
	Provision for doubtful debts	(808,593)	(726,317)
		2,834,940	2,660,997
5 (a)	Consolidated trade receivables		
	Debts due over six months	4,571,824	4,208,674
	Debts due below six months	16,619,929	14,080,149
	Provision for doubtful debts	(1,770,379)	(1,639,954)
		19,421,374	16,648,869
6	Inter-company receivables		
	ACI Logistics Limited	11,922,561	11,163,795
	ACI HealthCare Limited	10,605,441	9,985,509
	Premiaflex Plastics Limited	5,230,799	4,489,516
	ACI Foods Limited	4,064,810	4,124,884
	ACI Biotech Limited	1,398,720	1,197,693
	ACI Agrolink Limited	1,109,294	1,009,568
	ACI HealthCare USA Inc.	935,979	858,701
	Infolytx Bangladesh Limited	819,765	759,291
	ACI Chemicals Limited	262,382	252,889
	ACI Pure Flour Limited	-	-
	ACI Godrej Agrovet (Pvt.) Limited	935	935
	ACI Motors Limited	614,376	-
	Computer Technology Limited	30	30
		36,965,093	33,842,811

		Figures in '000' Taka	
		31 December 2023	30 June 2023
		Taka	Taka

6 (a) Consolidated receivable from joint-ventures and associates

Computer Technology Limited	30	30
ACI Godrej Agrovet (Pvt.) Limited	935	935
	<u>965</u>	<u>965</u>

7 Advances, deposits and prepayments

Advances to staff, suppliers and others	461,063	266,050
VAT current account	159,622	59,201
LC Margin	1,059,847	389,308
Deposits	275,047	287,702
Prepayments	155,922	61,258
	<u>2,111,501</u>	<u>1,063,519</u>

7 (a) Consolidated advances, deposits and prepayments

Advances to staff, suppliers and others	1,265,866	1,025,956
VAT current account	340,571	171,335
LC Margin	3,500,318	988,816
Deposits	779,080	785,502
Prepayments	535,984	301,518
Advance for capital expenditure	27,298	18,397
	<u>6,449,117</u>	<u>3,291,524</u>

8 Employee benefits

Staff gratuity provision	1,170,977	1,051,560
Other long term employee benefits	282,808	257,250
	<u>1,453,785</u>	<u>1,308,810</u>

8 (a) Consolidated employee benefits

Staff gratuity provision	1,505,231	1,363,430
Other long term employee benefits	397,244	357,550
	<u>1,902,475</u>	<u>1,720,980</u>

Figures in '000' Taka
31 December 2023 **30 June 2023**
Taka Taka

9	Long term borrowings		
	Long term bank loans	1,794,094	1,505,491
		<u>1,794,094</u>	<u>1,505,491</u>
9 (a)	Consolidated long term borrowings		
	Long term bank loans	7,688,827	6,047,144
		<u>7,688,827</u>	<u>6,047,144</u>
10	Loans and borrowings - short term		
	Short term loans	26,934,897	24,300,277
	Current portion of long term loans	466,077	424,636
		<u>27,400,974</u>	<u>24,724,913</u>
10 (a)	Consolidated loans and borrowings - short term		
	Short term loans	45,486,307	42,450,097
	Current portion of long term loans	3,489,727	2,435,393
		<u>48,976,034</u>	<u>44,885,490</u>
11	Inter company payables		
	ACI Marine and Riverine Technologies Limited	78,227	63,507
	ACI Motors Limited	-	819,019
	ACI Salt Limited	2,339,628	2,104,857
	ACI Pure Flour Limited	1,468,820	510,702
	ACI Edible Oils Limited	223,930	15,495
	Creative Communication Limited	45,066	52,484
	ACI Formulations Limited	957,259	634,716
	Stochastic Logic Limited	3,015	3,047
		<u>5,115,946</u>	<u>4,203,826</u>

Figures in '000' Taka	
31 December 2023	30 June 2023
<u>Taka</u>	<u>Taka</u>

12 Other payables

Accruals	2,666,055	1,674,765
Advance from customers	87,736	104,175
Security money received from customers	34,876	35,571
Workers' profit participation fund	837,947	845,447
Tax and VAT deducted at source	173,680	108,058
Employees welfare fund	408,208	459,698
Rights share deposit to be refunded	564	564
Family day fund	6,938	6,464
Non-management staff provident fund	61,193	8,421
Unclaimed refund warrant - Zero Coupon Bonds	3,647	3,647
Payable for redemption of Zero Coupon Bonds	20,403	20,403
Management staff provident fund	16,128	41,595
Advertisement and promotional funds	127,437	113,555
Development funds	9,706	9,935
	<u>4,454,517</u>	<u>3,432,299</u>

12 (a) Consolidated other payables

Accruals	6,408,290	5,686,049
Advance from customers	431,408	1,308,061
Security money received from customers	105,069	106,216
Workers' profit participation fund	1,153,830	1,251,115
Management staff provident fund	16,128	41,595
Tax and VAT deducted at source	333,140	221,361
Employees welfare fund	408,208	459,698
Rights share deposit to be refunded	564	564
Family day fund	6,938	6,464
Non-management staff provident fund	61,193	8,421
Unclaimed refund warrant - Zero Coupon Bonds	3,647	3,647
Payable for redemption of Zero Coupon Bonds	20,403	20,403
Creditors for capital expenditure	18,534	44,610
Advertisement and promotional funds	127,437	113,555
Development funds	9,706	9,935
	<u>9,104,494</u>	<u>9,281,693</u>

		Figures in '000' Taka	
		For half year from	
		July 2023	July 2022
		to	to
		December 2023	December 2022
		Taka	Taka
13	Revenue		
	Pharmaceuticals	8,212,789	6,901,349
	Animal health	2,489,971	2,367,423
	Consumer brands	4,446,168	3,458,626
	Seeds	1,121,135	910,594
	Fertilizer	984,814	831,452
	Animal genetics and others	290,365	181,840
		17,545,242	14,651,284
13 (a)	Consolidated revenue		
	Gross sales	63,924,496	58,391,577
	Inter-company sales	(1,481,167)	(1,326,595)
		62,443,329	57,064,982
14	Cost of sales		
	Opening stock	6,876,275	7,100,348
	Purchase	10,050,767	8,250,940
		16,927,042	15,351,288
	Closing stock	(7,898,933)	(8,074,161)
		9,028,109	7,277,127
	Manufacturing expenses	1,390,241	1,489,535
		10,418,350	8,766,662
14 (a)	Consolidated cost of sales		
	Opening stock	21,056,091	19,364,928
	Purchase	46,741,012	46,820,638
		67,797,102	66,185,566
	Closing stock	(23,739,379)	(25,188,795)
		44,057,723	40,996,771
	Manufacturing expenses	3,607,589	2,944,222
		47,665,312	43,940,994
15	Administrative, selling and distribution expenses		
	Administrative expenses	318,275	309,351
	Distribution expenses	684,760	637,409
	Selling expenses	4,706,926	4,147,311
		5,709,960	5,094,072

Figures in '000' Taka	
For half year from	
July 2023	July 2022
to	to
December 2023	December 2022
Taka	Taka

15 (a) Consolidated administrative, selling and distribution expenses

Administrative expenses	1,503,266	1,266,274
Distribution expenses	1,334,693	1,442,537
Selling expenses	8,420,678	7,377,819
	11,258,637	10,086,630

16 Reconciliation of net operating cash flow

Profit after tax	1,671,008	1,101,180
<i>Adjustment for non-cash items and others:</i>		
- Gain on disposal of investment in joint ventures and associates	-	(249,078)
- Unrealized gain on translation of foreign currency receivables	(22,991)	(61,978)
- Depreciation and amortisation	250,291	239,533
- Provisions	(19,170)	312,546
- Finance cost	122,078	175,312
- Tax expense	431,826	300,891
- Contribution to WPPF	110,675	73,793
- Lease and other adjustments	91,758	81,973
<i>Changes in:</i>		
- Inventories	(1,522,824)	(715,242)
- Trade and other receivables	(1,196,884)	(501,227)
- Advances, deposits and prepayments	(1,041,814)	(88,289)
- Trade and other payables, and employment benefits	2,032,260	970,287
Cash generated from operating activities	906,214	1,639,700
Paid to WPPF	(144,544)	(11,488)
Interest paid	(92,664)	(151,173)
Income tax paid	(423,311)	(301,638)
Net cash from operating activities	245,695	1,175,401

16 (a) Reconciliation of Consolidated net operating cash flow

Profit/ (loss) after tax	(491,460)	179,325
<i>Adjustment for non-cash items and others:</i>		
- Gain on disposal of investment in equity accounted investees	-	(416,029)
- Depreciation and amortisation	855,519	794,862
- Provisions	155,212	725,098
- Share of profit of equity accounted investees	(317,447)	(74,241)
- Finance cost	3,096,259	2,419,221
- Tax expense	1,147,951	992,012
- Contribution to WPPF	196,740	181,399
- Lease and other adjustments	248,571	179,942

<i>Changes in:</i>		
- Inventories	(2,768,239)	(5,534,601)
- Trade and other receivables	(2,878,786)	(3,322,223)
- Advances, deposits and prepayments	(3,143,818)	(1,685,319)
- Trade and other payables, and employment benefits	1,067,105	2,466,426
Net cash from operating activities	(2,832,393)	(3,094,128)
Paid to WPPF	(328,233)	(75,372)
Interest paid	(2,321,230)	(1,749,285)
Income tax paid	(1,288,202)	(1,205,232)
Net cash from operating activities	(6,770,058)	(6,124,017)

- 17 Consolidated operating segments
Please see Annexure A.

Figures in '000' Taka	
For half year from	
July 2023	July 2022
to	to
December 2023	December 2022

- 18 Consolidated EPS, NAV per share, and NOCFPS

Weighted average number of ordinary shares (in thousand)	76,206	76,206
Consolidated profit/ (loss) attributable to owners of the Company	(641,780)	(136,209)
Earnings per share (Taka)	(8.42)	(1.79)
Consolidated cash flows from operating activities (Taka '000)	(6,770,058)	(6,124,017)
Net operating cash flows per share (NOCFPS)	(88.84)	(80.36)
	31 December 2023	30 June 2023
	Taka	Taka
Consolidated net asset attributable to owners of the Company (Taka '000)	7,542,063	8,662,417
Net asset value (NAV) per share	98.97	113.67

Reasons for significant deviations: During the six months period ended on 31 December 2023, the Group achieved a decent revenue growth which was contributed by a number of businesses as demonstrated in Consolidated Operating Segments. During the period, growth in gross profit exceeded the growth in operating expenses which contributed to the improvement of the operating profit. On the other hand, cost of borrowing increased due to the increase of interest rate along with the funding of additional working capital for supporting business growth. Overall, the consolidated EPS was Taka (8.42) during the period against Taka (1.79) of SPLY. NOCFPS during the period was Taka (88.84) against Taka (80.36) as a result of the movement in the working capital level.

- 19 Figures have been rounded off to the nearest '000' Taka and previous period's figures have been rearranged to conform to current period's presentation.

Annexure-A

Consolidated operating segments

Figures in '000' Taka
For the half year from July 2023 to December 2023

Particulars	Reportable Segment											Total reportable segments	Unallocated/ Elimination	Total
	Pharmaceuticals	Animal Health	Consumer Brands	Crop Care and Public Health	Motors	Pure Flour	Retail Chain	Salt	Foods	Premiaflex	HealthCare			
External revenue	8,212,789	2,489,971	4,305,559	2,242,575	15,337,251	4,235,324	10,546,089	1,617,178	4,858,274	3,596,878	1,473,636	58,915,525	3,527,804	62,443,329
Inter-segment revenue	-	-	522,929	-	102,814	74,337	26,937	13,588	116,397	306,815	249,447	1,413,264	67,903	1,481,167
Segment revenue	8,212,789	2,489,971	4,828,488	2,242,575	15,440,065	4,309,662	10,573,026	1,630,766	4,974,671	3,903,693	1,723,083	60,328,789	3,595,707	63,924,496
Depreciation and amortisation	160,766	13,365	40,172	10,722	59,722	17,861	83,365	45,267	38,557	137,307	189,766	796,870	58,649	855,519
Operating expenses	3,891,504	499,018	1,051,073	341,834	1,785,189	149,496	1,943,343	187,811	353,715	299,841	288,616	10,791,441	467,196	11,258,637
Finance cost / (income)	200,210	99,710	90,146	90,702	409,784	(1,224)	955,638	(69,069)	241,720	343,880	877,740	3,239,237	(142,978)	3,096,259
Segment profit/(loss) before tax	559,434	94,588	28,571	306,893	1,308,717	17,743	(846,087)	39,868	(64,461)	(67,267)	(1,447,247)	(69,249)	725,740	656,491
Segment assets at 31 Dec 2023	32,528,642	7,718,265	13,164,526	2,920,388	23,538,907	2,901,553	7,312,981	4,185,033	3,871,121	7,911,074	9,975,039	116,027,530	(18,586,171)	97,441,359
Segment liabilities at 31 Dec 2023	19,119,483	6,633,650	9,060,669	926,919	13,708,317	1,651,894	24,478,712	1,885,586	5,817,454	7,699,135	19,751,057	110,732,876	(22,505,755)	88,227,121

For the half year from July 2022 to December 2022

Particulars	Reportable segment											Total reportable segments	Unallocated/ Elimination	Total
	Pharmaceuticals	Animal Health	Consumer Brands	Crop Care and Public Health	Motors	Pure Flour	Retail Chain	Salt	Foods	Premiaflex	HealthCare			
External revenue	6,901,349	2,367,423	3,340,052	2,185,006	14,466,984	4,385,495	8,405,178	1,540,635	4,789,999	3,502,620	1,234,611	53,119,353	3,945,629	57,064,982
Inter-segment revenue	-	-	419,370	-	49,709	78,738	13,200	17,339	73,713	420,619	125,592	1,198,281	128,313	1,326,595
Segment revenue	6,901,349	2,367,423	3,759,423	2,185,006	14,516,693	4,464,234	8,418,379	1,557,974	4,863,713	3,923,239	1,360,202	54,317,634	4,073,942	58,391,577
Depreciation and amortisation	155,044	12,504	44,130	9,522	40,938	19,407	70,537	42,514	33,619	135,818	181,349	745,382	49,480	794,862
Operating expenses	3,563,725	495,616	767,807	325,559	1,603,312	202,444	1,527,949	142,398	341,216	300,527	272,179	9,542,734	543,896	10,086,630
Finance cost / (income)	155,660	89,390	69,657	68,482	280,793	(15,101)	722,332	(47,830)	186,065	243,755	705,053	2,458,257	(39,036)	2,419,221
Segment profit/(loss) before tax	281,478	102,391	(121,533)	291,886	1,311,997	100,153	(669,065)	272,421	48,051	46,239	(1,199,107)	464,909	706,428	1,171,337
Segment assets at 30 June 2023	13,863,192	2,277,929	3,868,800	2,962,783	20,973,043	2,412,410	6,745,911	4,189,170	4,204,271	8,139,155	10,484,917	80,121,580	10,786,542	90,908,122
Segment liabilities at 30 June 2023	4,643,160	1,045,126	2,564,224	813,444	11,429,761	1,139,201	23,001,954	1,890,875	6,053,881	7,794,694	18,628,006	79,004,325	1,356,524	80,360,849